Oluyemi Okupe Reports 23,584-Share Sale; 105,400 Shares Remain
Rhea-AI Filing Summary
Hims & Hers Health, Inc. (HIMS) Chief Financial Officer Oluyemi Okupe sold 23,584 shares of Class A common stock on 09/22/2025 at an average weighted price of $57.7411 per share under a Rule 10b5-1 trading plan adopted May 21, 2025. Following the sale, the reporting person directly beneficially owns 105,400 shares and indirectly owns 7,853 shares held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021. The filer certifies the sales were effected under the pre-established plan and offers to provide the exact breakdown of shares sold at each price within the reported $57.38–$58.245 range if requested by regulators or the issuer.
Positive
- Sale executed under a Rule 10b5-1 trading plan, indicating pre-planned disposition rather than opportunistic insider timing
- Full disclosure of average weighted price and share ranges ($57.38–$58.245) and offer to provide breakdowns on request supports transparency
Negative
- Insider reduced direct holdings by 23,584 shares, which is a realized decrease in the CFO's stake
Insights
TL;DR: Insider sale under a 10b5-1 plan reduces holdings but appears pre-planned, so investor reaction likely muted.
The CFO executed a sale of 23,584 Class A shares at an average weighted price of $57.7411 under a Rule 10b5-1 plan adopted on May 21, 2025. The report shows the CFO still holds a meaningful direct stake of 105,400 shares plus 7,853 indirectly via a trust, which preserves ongoing alignment with shareholders. The presence of a 10b5-1 trading plan reduces the likelihood that this sale conveys new company-specific information, so the transaction is more compliance-driven than a signal about near-term fundamentals.
TL;DR: Proper disclosure and use of a 10b5-1 plan indicate governance procedures were followed.
The Form 4 discloses the relationship of the reporting person (Chief Financial Officer) and documents the Rule 10b5-1 plan adoption date, the average weighted sale price, and remaining beneficial ownership. The filing is signed by an attorney-in-fact and offers to provide detailed price-by-price sale information on request, reflecting attention to disclosure obligations. From a governance perspective, this filing meets standard transparency expectations for insider sales executed under trading plans.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 23,584 | $57.7411 | $1.36M |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $57.38 - $58.245. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
